Imipenem-cilastatin as initial therapy for febrile cancer patients.
Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infec...
Gorde:
| Argitaratua izan da: | Antimicrob Agents Chemother |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society for Microbiology (ASM)
1986
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC180520/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3532942/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.30.2.211 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|